statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were...

Barinthus Biotherapeutics (NASDAQ:BRNS) PT Lowered to $8.00 at HC Wainwright

Barinthus Biotherapeutics (NASDAQ:BRNS  Free Report) had its price objective cut by HC Wainwright from $15.00 to $8.00 in a research report released on Thursday, Benzinga reports. They...

Barinthus Biotherapeutics Reports Significant Financial Shifts and Clinical Progress in 2023

Despite Revenue Decline, R&D Advances Signal Strong Future PotentialRelated Stocks: BRNS...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Context Therapeutics (CNTX Research Report) and Barinthus Biotherapeutics...

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

OXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31...

Barinthus Biotherapeutics: Q4 Earnings Insights

Barinthus Biotherapeutics (BRNS, $3.04) RSI Indicator left the oversold zone on January 24, 2024

This is a signal that BRNS's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Barinthus Biotherapeutics (BRNS, $3.03) RSI Indicator left the oversold zone on January 23, 2024

Barinthus Biotherapeutics (BRNS, $3.05) RSI Indicator left the oversold zone on January 22, 2024

Barinthus Biotherapeutics plc (BRNS, $3.32) entered Downtrend as Momentum indicator drops below 0 level on Jan 11, 2024

This indicator may be signaling that BRNS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.

Volume	24,533.00
52-Wk High	$5.10
52-Wk Low	$1.21

BRNS Barinthus Biotherapeutics PLC - ADR

About

Feed

News

Fundamentals